Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Phase II results of olaparib and abiraterone for mCRPC

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.06.18
Views: 1644
Rating:

Prof Noel Clarke - Salford Royal NHS Foundation Trust, Salford, UK

Prof Clarke speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about treating metastatic castration-resistant colorectal cancer with abiraterone with or without olaparib.

He highlights that patients were recruited independently of homologous recombination repair mutations, and breaks down the rPFS rates and mOS data by subgroup.

Of note are the cardiac toxicities, which will be clarified in phase III studies.

Related videos

follow us

Breast cancer epidemiology video


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence